1	
2	
3	
4	
5	Early initiation of polymyxin B hemoperfusion therapy for cancer patients with
6	refractory septic shock
7	
8	Short title: Early PMX-DHP initiation for septic shock
9	
10	
11	
12	
13	
14	
15	Jae Hoon Lee, Won Ho Han*
16	
17	Critical Care Medicine, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si
18	10408, Gyeonggi-do, Republic of Korea
19	
20	
21	
22	
23	
24	*Corresponding author:
25	F. mail: 13408@ncc re kr (WHH)

Abstract

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

Purpose: In this study, we analyzed correlations between 28-day mortality and hemodynamic changes, measured using polymyxin B-immobilized fiber column direct hemoperfusion initiation time, in patients with cancer with refractory septic shock. Materials and methods: We retrospectively analyzed 45 patients with cancer who received polymyxin B-immobilized fiber column direct hemoperfusion due to refractory septic shock. Patients were categorized into early (<12 h between refractory septic shock and initiation of polymyxin B-immobilized fiber column direct hemoperfusion) and late (>12 h) initiation groups. Changes in vasoactive inotrope scores, sequential organ failure assessment scores. and PaO₂/FiO₂ ratios before and 24 h after polymyxin B-immobilized fiber column direct hemoperfusion, were compared. Results: Univariable analysis showed that 28-day mortality risk was associated with diabetes mellitus (odds ratio=3.081; 95% confidence interval =1.290–7.360; p=0.011), lactic acid (odds ratio=1.010; 95% confidence interval =1.005– 1.014; p<0.0001), and sequential organ failure assessment score (odds ratio=1.190; 95% confidence interval =1.044–1.357; p=0.009). Multivariable analysis showed that 28-day mortality risk was associated with diabetes mellitus (odds ratio=2.718; 95% confidence interval = 1.013-7.291; p=0.047), early initiation (odds ratio=0.268; 95% confidence interval =0.094-0.765; p=0.014), and lactic acid (odds ratio=1.009; 95% confidence interval =1.004-1.014; p<0.0001). Overall survival was slightly higher in the early than in the late initiation group (p=0.0515). Comparisons of variables before and 24 h after polymyxin B-immobilized fiber column direct hemoperfusion revealed that vasoactive inotrope scores decreased in both the early and late groups ($\Delta 318 \text{ vs. } \Delta 114; p=0.001$ and p=0.005, respectively), whereas the PaO_2/FiO_2 ratio slightly increased ($\Delta 127.5 \text{ vs. } \Delta 95.6; p=0.350 \text{ and } p=0.390, \text{ respectively}$) over time. **Conclusions**: In patients with cancer with refractory septic shock, early initiation

of polymyxin B-immobilized fiber column direct hemoperfusion reduced inotropevasopressor requirement and 28-day mortality. **Keywords**: sepsis: 28-day mortality; risk factors; hemodynamics; respiratory function; organ failure Introduction Sepsis causes life-threatening organ dysfunction through dysregulation of host responses to infection [1]. Eleven million of the 49 million people that contract sepsis globally each year die, equivalent to a total global mortality of 19.7%. However, sepsisrelated mortality has shown a decreasing trend with an increase in early detection and improvements in therapeutic strategies [2]. Sepsis is a significant risk factor in immunocompromised patients with cancer undergoing treatment, as well as in those with a known poor prognosis. The incidence of sepsis is 3- to 5-fold higher in patients with cancer, at 16.4 cases per 1.000 persons, than in those without. Furthermore, the proportion of sepsisrelated mortality is approximately 3-fold higher than that of annual cancer deaths (10% vs. 37.8%), although mortality rates vary across cancer types [3]. Polymyxin B-immobilized fiber column direct hemoperfusion (PMX-DHP) is a potential therapy developed in 1994 to reduce blood endotoxin levels and treat septic shock, which effectively enhances hemodynamics and respiratory functions in patients with septic shock, caused by intra-abdominal infection [4]. However, whether it contributes to survival and prevents organ failure is controversial, and there are no established guidelines on the best time to perform PMX-DHP [5-8]. To date, studies on PMX-DHP have mainly targeted patients with no cancer, and

there is a scarcity of literature on patients with cancer. This prompted the present

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

investigation, in which we analyzed the correlation between PMX-DHP initiation time and 28-day mortality in patients with cancer with refractory septic shock. Additionally, we aimed to verify whether hemodynamics, sequential organ failure assessment (SOFA) scores, and oxygenation levels improve following PMX-DHP treatment.

Materials and methods

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

This single-center, retrospective study was conducted in 45 patients with cancer aged ≥18 years, who received PMX-DHP to treat septic shock, at the intensive care unit of our institution between October 2019 and March 2023. Septic shock was identified based on the criteria established for identification of sepsis and septic shock (Sepsis-3), including the requirement of vasopressors to maintain a mean arterial pressure (MAP) of ≥65 mm Hg and a serum lactate level of >2 mmol/L in the absence of hypovolemia according [1]. PMX-DHP was administered to patients who voluntarily consented to the treatment. Refractory septic shock was defined as the requirement of $\geq 0.5 \,\mu g/kg/min$ of norepinephrine or an additional dose of vasopressin to maintain MAP of >65 mmHg [9]. We administered IV hydrocortisone at a dose of 200 mg/d, provided as 50 mg intravenously every 6 hours, to all patients diagnosed with refractory septic shock. For PMX-DHP, the blood flow rate was set at 100 mL/min and controlled by the attending physician depending on the patient's state to maintain a steady rate. For anticoagulation, 20–40 mg/h of nafamostat mesylate, a synthetic serine protease inhibitor, was administered. The duration of PMX-DHP was 2 h or more; the infusion time and frequency were determined by the attending physicians [10,11]. Patients who received PMX-DHP treatment within 12 h from the diagnosis of refractory septic shock were assigned to the "early initiation" group, while those who were treated after 12 h or more had elapsed since their diagnosis were assigned to the "late initiation" group.

The following patient characteristics were entered as variables for the analyses: age, sex, underlying disease (diabetes mellitus (DM), hypertension, cerebrovascular accident, chronic kidney disease, and chronic obstructive pulmonary disease), cancer type (intraabdominal/genitourinary/lung/others), pre-PMX-DHP laboratory data (absolute neutrophil count, platelet count, C-reactive protein, lactic acid levels, procalcitonin, creatinine levels, PaO₂/FiO₂ ratio), severity (acute physiology and chronic health evaluation III (APACHE III)), SOFA score, PMX-DHP frequency, vasoactive inotrope scores (VIS), primary infection site (lung, abdominal, genitourinary, others), microbiological culture, mechanical ventilator, intervention, surgical intervention, and 28-day mortality.

VIS were measured as follows [12]:

 $VIS = dopamine \ dose \ (\mu g/kg/min) + dobutamine \ dose \ (\mu g/kg/min) + 100$ \times epinephrine dose ($\mu g/kg/min$) + 10 \times milrinone dose ($\mu g/kg/min$) 110 $+ 10,000 \times vasopressin dose (units/kg/min) + 100$ \times norepinephrine dose (ug/kg/min)

Using patient data, correlations of the aforementioned variables with PMX-DHP initiation time (early initiation group <12 h; late initiation group >12 h) were assessed by calculating differences in values reported before and 24 h after PMX-DHP. This study was approved by the Institutional Review Board of the National Cancer Center (Approval No.: NCC2023-0170). The data access period for the manuscript is from July 3, 2023, the date IRB approval, to July 21, 2023. The requirement for the acquisition of informed consent from patients was waived owing to the retrospective nature of this study.

Statistical analysis

Continuous variables are expressed as mean \pm standard deviation or median (minimum-maximum or range). Categorical variables were compared between groups using the Pearson χ^2 and Fisher's exact test, and continuous variables were compared using t-tests for parametric and the Wilcoxon rank sum test for nonparametric data. Statistical significance

100

101

102

103

104

105

106

107

108

109

111

112

113

114

115

116

117

118

119

120

121

122

was set at p<0.05. The final set of variables in the multivariable model were selected via backward elimination in the univariable analysis, with p<0.1. All statistical analyses were performed using SAS® version 9.4 for Windows® (SAS Institute, Cary, NC, USA).

Results

Characteristics of the patient group undergoing PMX-DHP

treatment

A total of 45 patients received PMX-DHP for refractory septic shock. Patients' mean age was 64.4 years, and 24 patients (53.5%) died within 28 days due to multi-organ failure caused by septic shock. The most frequent type of cancers were genitourinary (53.3%), intraabdominal cancers (31.1%), and lung cancer (8.9%). The most frequent primary infection site was the abdomen (64.4%), followed by the lung (20.0%), and the genitourinary tract (11.1%). Gram-negative bacteria were the most common microorganism (62.5%). The median inotropes-vasopressor requirement (VIS) to maintain an MAP \geq 65 mmHg was 289.7 (9–913). The mean APACHE III score before PMX-DHP was 93.9 \pm 29.2, while the mean SOFA score was 13.2 \pm 3.3. Additionally, 41 patients underwent mechanical ventilation (91.1%) and the median PaO₂/FiO₂ ratio was 141.2 (20.2–534.3) (Table 1).

Table 1. Characteristics of patients treated with PMX-DHP.

	Patients (N=45)	Percentage (%)	
Sex			
Male	19	42.2	
Female	26	57.8	

Age	64.4 ± 11.7	
Underlying disease		
Diabetes mellitus	13	28.9
Hypertension	21	46.7
Cerebrovascular accident	6	13.3
Chronic kidney disease	2	4.4
Chronic obstructive pulmonary	1	2.2
disease		
Type of cancer		
Intra-abdominal	14	31.1
Genitourinary	24	53.3
Lung	4	8.9
Others	3	6.7
APACHE III	93.9 ± 29.2	
SOFA	13.2 ± 3.3	
No. of PMX-DHP* treatment		
#1	38	84.4
> #2	7	15.6
VIS	289.7 ± 220.5	
Primary infection site		
Lung	9	20
Abdominal	29	64.4
Genitourinary	5	11.1
Others	2	4.4

Laboratory values

ANC (/uL)	1575.5 (0–30589)	
Platelet count (10 ³ /uL)	107 (2–299)	
CRP# (mg/dL)	15.5 (0.1–30.5)	
Lactic acid (mg/dL)	95 (13.6–353.4)	
Procalcitonin (mg/mL)	30.2 (0.4–526.6)	
Creatinine (mg/dL)	1.5 (0.3–7.7)	
P/F ratio	141.2 (20.2–534.3)	
Positive culture		
G(-)	25	62.5
G(+)	11	27.5
Mixed	4	10
Mechanical ventilation	41	91.1
Intervention	14	68.9
Operation	16	64.4
28-day mortality		
Alive	21	46.7
Death	24	53.3

ANC: absolute neutrophil count; APACHE III: Acute Physiology and Chronic Health Evaluation III (APACHE III); CRP: C-reactive protein; G(-): Gram-negative bacteremia; G(+): Gram-positive bacteremia; P/F ratio: ratio of arterial oxygen partial pressure to fraction of inspired oxygen (PaO₂/FiO₂); PMX-DHP: polymyxin B-immobilized fiber column direct hemoperfusion; SOFA: sequential organ failure assessment; VIS: vasoactive inotrope score (dopamine dose ($\mu g/kg/min$) + dobutamine dose ($\mu g/kg/min$) + 100 × epinephrine dose

143

144

145

146

147

(μg/kg/min) + 10 × milrinone dose (μg/kg/min) + 10,000 × vasopressin dose (units/kg/min) + 100 × norepinephrine dose (μg/kg/min))

When patients were divided into two groups— early and late —based on the PMX-DHP initiation time, the most frequent cancer type in both groups was genitourinary cancer (early vs. late, 55.0% vs. 52.0%, respectively). The disease severity indices (i.e., median APACHE III and SOFA scores) did not vary significantly between the two groups (APACHE III score: 95.5 (41–144) vs. 94 (36–159), p=0.427; SOFA score: 13 (6–18) vs. 14 (7–21), p=0.270). The VIS was higher in the early group than the late group (372.5 [15–913] vs. 213 [9–847], p=0.020). In both groups, the abdominal area was the most frequent primary infection site (60% vs. 68%). Gram-negative bacteremia was the most commonly detected bacteria on microbiological culture in both groups (64.7% vs. 60.9%, p=0.309). Compared to that of the early initiation group, the late initiation group showed a slightly higher rate of gram-positive bacteremia (17.6% vs. 34.8%), a higher rate of intervention to infection source control (15% vs. 44%, p=0.037), a lower frequency of surgical intervention (45% vs. 25%, p=0.237), and a higher level of 28-day mortality (30% vs. 60%, p=0.045) (Table 2).

Table 2. Baseline characteristics of the early vs. the late initiation treatment group.

	Early (N=20)	Late $(N = 25)$	<i>p</i> -value
Sex			
Male	9 (45.0%)	10 (40.0%)	0.736
Female	11 (55.0%)	15 (60.0%)	
Age	66.2 ± 11.2	62.9 ± 12.0	0.362

Underlying disease

13 (65.0%)	19 (76.0%)	0.419
11 (55.0%)	10 (40.0%)	0.316
5 (25.0%)	1 (4.0%)	0.074
1 (5.0%)	1 (4.0%)	1
1 (5.0%)	0 (0.0%)	0.444
5 (25.0%)	9 (36.0%)	0.792
11 (55.0%)	15 (52.0%)	
2 (10.0%)	2 (8.0%)	
2 (10.0%)	1 (4.0%)	
97.8 ± 30.8	90.7 ± 28.1	0.427
12.6 ± 3.2	13.7 ± 3.4	0.27
17 (85.0%)	21 (84.0%)	1
3 (15.0%)	4 (16.0%)	
365.9 ± 207.2	228.8 ± 215.5	0.02
3 (15.0%)	6 (24.0%)	0.411
12 (60.0%)	17 (68.0%)	
4 (20.0%)	1 (4.0%)	
1 (5.0%)	1 (4.0%)	
11 (64.7%)	14 (60.9%)	0.309
	11 (55.0%) 5 (25.0%) 1 (5.0%) 1 (5.0%) 1 (5.0%) 5 (25.0%) 11 (55.0%) 2 (10.0%) 2 (10.0%) 97.8 \pm 30.8 12.6 \pm 3.2 17 (85.0%) 3 (15.0%) 3 (15.0%) 12 (60.0%) 4 (20.0%) 1 (5.0%)	11 (55.0%) 10 (40.0%) 5 (25.0%) 1 (4.0%) 1 (5.0%) 1 (4.0%) 1 (5.0%) 0 (0.0%) 5 (25.0%) 9 (36.0%) 11 (55.0%) 15 (52.0%) 2 (10.0%) 2 (8.0%) 2 (10.0%) 1 (4.0%) 97.8 ± 30.8 90.7 ± 28.1 12.6 ± 3.2 13.7 ± 3.4 17 (85.0%) 21 (84.0%) 3 (15.0%) 4 (16.0%) 3 (15.0%) 4 (16.0%) 3 (15.0%) 6 (24.0%) 12 (60.0%) 17 (68.0%) 4 (20.0%) 1 (4.0%) 1 (5.0%) 1 (4.0%)

G(+)	3 (17.6%)	8 (34.8%)	
Mixed	3 (17.6%)	1 (4.3%)	
Mechanical ventilation	19 (95.0%)	22 (88.0%)	0.617
Intervention	3 (15.0%)	11 (44.0%)	0.037
Operation	9 (45.0%)	7 (28.0%)	0.237
28-day mortality			
Alive	14 (70.0%)	10 (40.0%)	0.045
Death	6 (30.0%)	15 (60.0%)	
ANC (uL)	1191 (0–22568)	2266 (0–30589)	0.097
Non-Neutropenia (ANC>1500)	9 (45%)	15 (62.5%)	0.246
Neutropenia (ANC<1500)	11 (55.0%)	9 (37.5%)	
Platelet count (10 ³ /uL)	117.5 (13–299)	96 (2–246)	0.289
CRP (mg/dL)	14.9 (0.1–27.3)	15.8 (1.1–30.5)	0.173
Lactic acid (mg/dL)	90.3 (13.6–353.4)	95 (26.1–262.9)	0.807
Procalcitonin (mg/mL)	44.5 (0.4–144.2)	20.7 (1.3–526.6)	0.34
Creatinine (mg/dL)	1.4 (0.3–7.7)	1.5 (0.4–4)	1
P/F ratio	121.8 (20.2–524)	156 (48.1–534.3)	0.576

Evaluation III (APACHE III); CRP: C-reactive protein; G (-): Gram-negative bacteremia; G (+): Gram-positive bacteremia; P/F ratio: ratio of arterial oxygen partial pressure to fraction of inspired oxygen (PaO₂/FiO₂); PMX-DHP: polymyxin B-immobilized fiber column direct hemoperfusion; SOFA: sequential organ failure assessment (SOFA); VIS: vasoactive

ANC: absolute neutrophil count; APACHE III: Acute Physiology and Chronic Health

Overall survival in the early vs. late group

inotrope score

167

168

169

170

171

172

173

The number of deaths within 28 days from the initiation of PMX-DHP was compared for both groups; six deaths were recorded in the early and 15 in the late initiation group (Table 2). The survival rate was \geq 50% in the early group, and the median survival was 7 days in the late group. While the 28-day overall survival was slightly higher in the early compared to the late group, no significant difference was found (p=0.0515) (Fig 1).

Fig 1. Estimation of overall survival according to initiation of polymyxin B-immobilized fiber column direct hemoperfusion (PMX-DHP).

Univariable and multivariable analyses of 28-day mortality

Our univariable analysis of 28-day mortality in patients with cancer with refractory septic shock after PMX-DHP showed that DM (odds ratio (OR)=3.081; 95% confidence interval (CI)=1.290–7.360; p=0.011), lactic acid levels (OR=1.010; 95% CI=1.005–1.014; p<0.0001), and SOFA scores (OR=1.190; 95% CI=1.044–1.357; p=0.009) were correlated with 28-day mortality. A multivariable analysis was performed using backwards selection and the univariable analysis results; the results indicated that 28-day mortality was correlated with DM (OR=2.718; 95% CI=1.013–7.291; p=0.047), early initiation (OR=0.268; 95% CI=0.094–0.765; p=0.014), and lactic acid levels (OR=1.009; 95% CI=1.004–1.014; p<0.0001) (Table 3).

Table 3. Univariable and multivariable analysis of 28-day mortality.

	Univariable a	Univariable analysis		e analysis
	OR (95% CI)	<i>p</i> -value	OR (95% CI)	<i>p</i> -value
Sex	1.294 (0.549–3.049)	0.555		

Age	1.001 (0.065–1.038)	0.974		
Underlying disease				
Diabetes mellitus	3.081 (1.290–7.360)	0.011	2.718 (1.013–7.291)	0.047
Hypertension	1.098 (0.466–2.587)	0.83		
Cerebrovascular	1.206 (0.3555–4.097)	0.765		
accident				
Chronic kidney	4.025 (0.898–18.042)	0.069		
disease				
COPD	3.126 (0.409–23.917)	0.272		
Initiation of PMX-DH	IP .			
Late				
Early	0.423 (0.163–1.093)	0.076	0.268 (0094–0.765)	0.014
Type of cancer				
Intra-abdominal	2.171 (0.274–17.166)	0.463		
Genitourinary	0.948 (0.119–7.578)	0.96		
Lung	2.205 (0.229–21.199)	0.494		
Others				
APACHE III	1.002 (0.988–1.017)	0.77		
SOFA score	1.190 (1.044–1.357)	0.009		
VIS	1.002 (1.000–1.004)	0.093		
Primary infection site				
Lung	1.258 (0.151–10.46)	0.832		
Abdominal	0.696 (0.090–5.362)	0.728		
Genitourinary	0.697 (0.063–7.694)	0.768		

Mechanical	5.373 (0.303–95.258)	0.252			
ventilation					
Intervention	1.138 (0.459–2.821)	0.78			
Operation	0.474 (0.173–1.298)	0.146			
ANC (/uL)					
Non-Neutropenia					
(ANC>1500)					
Neutropenia	0.560 (0.223–1.408)	0.218			
(ANC<1500)					
Platelet count	0.006 (0.000, 1.002)	0.104			
	0.996 (0.990–1.002)	0.194			
$(10^3/\mathrm{uL})$					
CRP (mg/dL)	0.992 (0.938–1.049)	0.769			
Lactic acid (mg/dL)	1.010 (1.005–1.014)	< 0.0001	1.009 (1.004–1.014) <0.0001		
Procalcitonin	0.990 (0.973–1.008)	0.281			
(mg/mL)					
Creatinine (mL/dL)	1.165 (0.911–1.490)	0.223			
P/F ratio	0.998 (0.005–1.002)	0.343			
ANC: absolute neutroph	ANC: absolute neutrophil count; APACHE III: Acute Physiology and Chronic Health				
Evaluation III (APACHE III); COPD: chronic obstructive pulmonary disease; CRP: C-					
reactive protein; P/F ratio: ratio of arterial oxygen partial pressure to fraction of inspired					
oxygen (PaO ₂ /FiO ₂); PMX-DHP: polymyxin B-immobilized fiber column direct					
hemoperfusion; SOFA: sequential organ failure assessment (SOFA); VIS: vasoactive					
inotrope score; OR: odds ratio; CI: confidence interval.					

Changes in values of variables after PMX-DHP treatment (early vs. late initiation)

Comparison of variables before and 24 h after PMX-DHP showed that, in both groups, VIS (p=0.001 vs. p=0.005, respectively) and creatinine levels (p=0.016 vs. p=<0.001) significantly decreased after PMX-DHP. However, the decrease in the VIS was higher in the early initiation group (Fig 2).

Fig 2. Changes in variables associated with initiation of polymyxin B-immobilized fiber column direct hemoperfusion (PMX-DHP): vasoactive inotrope score (VIS)

In both groups, the platelet count ($\Delta62.0$ vs. $\Delta25.5$; p=0.007 vs. p=0.061, respectively), lactic acid levels ($\Delta37.5$ vs. $\Delta33.2$; p=0.080 vs. p=0.083), and SOFA scores (p=0.230 vs. p=0.022) significantly decreased after PMX-DHP. After 24 h, the PaO₂/FiO₂ ratio was higher in both groups ($\Delta127.5$ vs. $\Delta95.6$; p=0.350 vs. p=0.390, respectively), with the degree of increase being slightly higher in the early initiation group (Table 4).

Table 4. Changes in variables after PMX-DHP treatment.

	Before HP	After HP	<i>p</i> -value
Early initiation			
ANC (/uL)	1191 (0–22568)	3158.5 (0–23000)	0.083
Platelet count (10 ³ /uL)	117 (13–299)	55 (16 –165)	0.007
CRP (mg/dL)	14.5 (0.1–27.3)	18.5 (8.2–38)	0.015
Lactic acid (mg/dL)	73.7 (13.6–353.4)	36.2 (17.3–278.5)	0.080
Procalcitonin (mg/mL)	44.5 (0.4–144.2)	54.7 (19.1–307.3)	0.400

It is made available under a	CC-B	Y 4.0 International license.
------------------------------	------	------------------------------

	Creatinine (mg/dL)	1.3 (0.3–6.6)	1.1 (0.3–2.6)	0.016
	P/F ratio	160 (20.2–524)	287.5 (37.2–498)	0.350
	SOFA score	11 (6–17)	10 (4–15)	0.230
	VIS	336 (15–736)	18 (0–693)	0.001
Late initiation				
	ANC (/uL)	2214.5 (1–30589)	11110.5 (4–35040)	0.830
	Platelet count (10 ³ /uL)	116 (3–246)	90.5 (0–138)	0.061
	CRP (mg/dL)	17.6 (4.4–30.5)	18.4 (2.3–39)	0.920
	Lactic acid (mg/dL)	82.4 (26.1–234.8)	49.2 (13–287.5)	0.083
	Procalcitonin (mg/mL)	22.7 (1.3–526.6)	19.7 (0.1–238.7)	0.110
	Creatinine (mg/dL)	1.5 (0.5–3.7)	1 (0.5–1.8)	< 0.0001
	P/F ratio	164.9 (48.1–134.3)	260.5 (66.6–544.4)	0.390
	SOFA score	13 (7–21)	12 (3–18)	0.022
	VIS	124 (9–496)	10 (0–451)	0.005

ANC: absolute neutrophil count; CRP: C-reactive protein; P/F ratio: ratio of arterial oxygen partial pressure to fraction of inspired oxygen (PaO₂/FiO₂); PMX-DHP: polymyxin B-immobilized fiber column direct hemoperfusion; SOFA: sequential organ failure assessment (SOFA); VIS: vasoactive inotrope score

Discussion

This study was conducted to analyze the correlation between PMX-DHP initiation time and 28-day mortality in patients with cancer with refractory septic shock and to verify whether hemodynamics, SOFA scores, and oxygenation levels improve after PMX-DHP. A mortality rate of 53.3% related to refractory septic shock was observed in this study, which did not significantly differ from that of a previous meta-analysis of patients with cancer after

sepsis treatment (48–62%) [13]. However, the earlier reported mortality has been found to be slightly higher than the 28-day mortality related to septic shock observed in our patients with cancer who received PMX-DHP (19–37.7%) [7,8,14]. This may be due the immunosuppressed nature of our patients which resulted in higher disease severity (APACHE III score; SOFA score) than those in studies performed at other centers. Another possible explanation could be that the treatment initiation in the present study occurred at a comparatively more severe stage, as the initiation of PMX-DHP follows the diagnosis of refractory septic shock. The results of this study demonstrate that the requirement for a vasoactive inotrope agent to maintain hemodynamics after PMX-DHP decreased in the early initiation group, which led to a fall in 28-day mortality. The inotropes-vasopressor requirement decreased (VIS, $\triangle 318 \text{ vs. } \triangle 114, p=0.001 \text{ vs. } p=0.005$) after PMX-DHP in both the early and the late group; however, the decrease was larger in the early than the late group. Before the treatment, the requirement for a vasoactive inotrope agent to maintain hemodynamics was higher in the early than the late group; this enabled a relatively faster detection of refractory septic shock by the attending physician and thereby the administration of PMX-DHP, which reduced 28day mortality. This implies that rapid administration of PMX-DHP within 12 h could improve hemodynamics and prevent life-threatening organ failure, thereby contributing to a reduction in mortality. Through the modulation of activated mononuclear cells and neutrophils, PMX-DHP improves pulmonary oxygenation by suppressing inflammatory mediators and systemic inflammation [15]. In the current study, the PaO₂/FiO₂ ratio was higher in both groups after PMX-DHP, with a slightly larger increase in the early initiation group, although the difference was not statistically significant ($\Delta 127.5 \text{ vs. } \Delta 95.6; p=0.350 \text{ vs. } p=0.390$). The PaO₂/FiO₂ ratio was assessed 24 h after PMX-DHP in the current study; this fact might

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

explain the differences between ours and the findings of previous studies, where the target was acute respiratory distress syndrome or acute lung injury and the PaO2/FiO2 ratio was evaluated 72–96 h after PMX-DHP [5,10,15]. Studies have shown that PMX-DHP prevents acute kidney injury and renal tubular cell apoptosis by maintaining the acid-base balance and lowering the plasma concentrations of lactate, creatinine, IL-6, and IL-10 [16]. In the current study, likewise, the creatinine level decreased in both groups after PMX-DHP (early group, p=0.016 vs. late group, p<0.001). However, this could not be confirmed to be an outcome of PMX-DHP, as most patients (78%) also underwent continuous renal replacement therapy. In addition, studies where continuous renal replacement therapy and PMX-DHP were concurrently applied did not report a reduction in mortality [17]. Moreover, creatinine levels did not significantly affect 28-day mortality in our patient sample, which corresponds with the results of previous studies. Conventionally, the duration of PMX-DHP is 2 h; however, recent studies have reported that, in the event of endotoxin adsorption saturation, extending its duration to >2 h could enhance pulmonary oxygenation and hemodynamics, thereby reducing 28-day mortality [18–20]. The PMX-DHP duration in the current study was 15 h on an average. One or two additional treatments were performed by the attending physician; however, no significant correlation was found between the treatment frequency and 28-day mortality (OR=1.640; 95%CI=0.598–4.499; *p*=0.036). The most common adverse effects of PMX-DHP are thrombocytopenia, transient hypotension, and allergic reactions [21]. Accordingly, the platelet count after hemoperfusion

in the current study decreased in both the early and late initiation groups ($\Delta 62 \text{ vs. } \Delta 25.5$; p=0.007 vs. p=0.061). The patients in our sample did not have transient hypotension or allergic reactions.

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

This study has certain limitations. First, this was a single-center, retrospective study with a small sample size, which limits the generalizability of our findings. Second, we focused on patients with refractory septic shock without initial measurements of endotoxin levels, which limited our analysis of endotoxemia-targeted PMX-DHP treatment effects. However, PMX-DHP is known to induce the absorption of endogenous cannabinoids, activated neutrophils, and monocytes, modify the monocyte surface marker expression, and be an effective treatment option for gram-positive bacteremia [15,22]. We can therefore infer that PMX-DHP provides beneficial effects for both gram-negative and positive bacteremia.

Despite these limitations, this is the first study to assess the effects of PMX-DHP in patients with cancer with refractory septic shock, and our findings confirm that the early initiation of PMX-DHP, compared to its late initiation, can reduce 28-day mortality and the inotropes-vasopressor requirement for maintaining hemodynamics. In the future, a multicenter, large-scale, randomized, controlled study should be conducted to determine the optimal initiation time.

Conclusions

In our sample of patients with cancer with refractory septic shock, the early initiation of PMX-DHP, compared to its late initiation, was effective in reducing 28-day mortality and the inotropes-vasopressor requirement for maintaining hemodynamics. Based on these findings, the optimal initiation time should be determined in a follow-up study.

Acknowledgements

The author thanks Dr. Jee hee-Kim for invaluable help and advice throughout the study and Ms. Mira Han for assistance with bioinformatics and statistics; and Editage for English language editing. Data availability All data generated or analyzed during this study are included in this published article. References 1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315: 801-810. doi:10.1001/jama.2016.0287. 2. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017; analysis for the Global Burden of Disease Study. Lancet. 2020;395: 200-211. doi:10.1016/S0140-6736(19)32989-7. 3. Williams MD, Braun LA, Cooper LM, Johnston J, Weiss RV, Qualy RL, et al. Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. Crit Care. 2004;8: R291-R298. doi:10.1186/cc2893. 4. Shimizu T, Miyake T, Tani M. History and current status of polymyxin Bimmobilized fiber column for treatment of severe sepsis and septic shock. Ann Gastroenterol Surg. 2017;1: 105-113. doi:10.1002/ags3.12015. 5. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301: 2445-2452. doi:10.1001/jama.2009.856.

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

6. Paven DM, Guilhot J, Launey Y, Lukaszewicz AC, Kaaki M, Veber B, et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015;41: 975-984. doi:10.1007/s00134-015-3751-z. 7. Dellinger RP, Bagshaw SM, Antonelli M, Foster DM, Klein DJ, Marshall JC, et al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level. The Euphrates randomized clinical trial. JAMA. 2018;320: 1455-1463. doi:10.1001/jama.2018.14618. 8. Fujii T, Ganeko R, Kataoka Y, Furukawa TA, Featherstone R, Doi K, et al. Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2018;44: 167-178. doi:10.1007/s00134-017-5004-9 [published correction appears in Intensive Care Med. 2018 January 16]. 9. Bassi E, Park M, Azevedo LCP. Therapeutic strategies for high-dose vasopressordependent shock. Crit Care Res Pract. 2013;2013: 654708. doi:10.1155/2013/654708. 10. Mitaka C, Kusao M, Kawagoe I, Satoh D, Iba T, Ronco C. Impact of extended duration of polymyxin B-immobilized fiber column direct hemoperfusion on hemodynamics, vasoactive substance requirement, and pulmonary oxygenation in patients with sepsis: an observational study. Blood Purif. 2022;51: 62-69. doi:10.1159/000515685. 11. Mitaka C, Tsuchida N, Kawada K, Nakajima Y, Imai T, Sasaki S. A longer duration of polymyxin B-immobilized fiber column hemoperfusion improves pulmonary oxygenation in patients with septic shock. Shock. 2009;32: 478-483. doi:10.1097/SHK.0b013e3181a2a978.

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

12. Gaies MG, Jeffries HE, Niebler RA, Pasquali SK, Donohue JE, Yu S. Vasoactiveinotropic score (VIS) is associated with outcome after infant cardiac surgery: an analysis from the pediatric cardiac critical care consortium and virtual PICU system registries. Pediatr Crit Care Med. 2014;15: 529-537. doi: 10.1097/PCC.0000000000000153. 13. Nazer L, Lopez-Olivo MA, Cuenca JA, Awad W, Brown AR, Abusara A, et al. Allcause mortality in cancer patients treated for sepsis in intensive care units: a systematic review and meta-analysis. Support Care Cancer. 2022;30: 10099-10109. doi:10.1007/s00520-022-07392-w. 14. Klein DJ, Foster D, Walker PM, Bagshaw SM, Mekonnen H, Antonelli M. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the Euphrates trial. Intensive Care Med. 2018;44: 2205-2212. doi:10.1007/s00134-018-5463-7. 15. Tsushima K, Kubo K, Koizumi T, Yamamoto H, Fujimoto K, Hora K, et al. Direct hemoperfusion using a polymyxin B immobilized column improves acute respiratory distress syndrome. J Clin Apher. 2002;17: 97-102. doi:10.1002/jca.10019. 16. Mitaka C, Masuda T, Kido K, Uchida T, Abe S, Miyasho T, et al. Polymyxin B hemoperfusion prevents acute kidney injury in sepsis model. J Surg Res. 2016;201: 59-68. doi:10.1016/j.jss.2015.10.020. 17. Lee JM, Baek SD, Kim TH, Jeon HR, Han JH, Chang JW. Uncertain clinical effect of polymyxin B hemoperfusion in patients with septic acute kidney injury requiring continuous renal replacement therapy. Shock. 2021;56: 551-556. doi:10.1097/SHK.0000000000001752. 18. Yamashita C, Hara Y, Kuriyama N, Nakamura T, Nishida O. Clinical effects of a longer duration of polymyxin B-immobilized fiber column direct hemoperfusion

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

376 therapy for severe sepsis and septic shock. Ther Apher Dial. 2015;19: 316-323. doi:10.1111/1744-9987.12339. 377 19. Miyamoto K, Kawazoe Y, Kato S. Prolonged direct hemoperfusion using a 378 379 polymyxin B immobilized fiber cartridge provides sustained circulatory stabilization in patients with septic shock: a retrospective observational before-after study. J 380 Intensive Care. 2017;5: 19. doi:10.1186/s40560-017-0214-3. 381 382 20. Kawazoe Y, Sato T, Miyagawa N, Yokokawa Y, Kushimoto S, Miyamoto K, et al. Mortality effects of prolonged hemoperfusion therapy using a polymyxin B-383 384 immobilized fiber column for patients with septic shock: a sub-analysis of the DESIRE trial. Blood Purif. 2018;46: 309-314. doi:10.1159/000491744. 385 21. Ronco C, Klein DJ. Polymyxin B hemoperfusion: a mechanistic perspective. Crit 386 387 Care. 2014;18: 309. doi:10.1186/cc13912. 22. Kawamata T, Imaizumi H, Yoshida M, Kaneko M. Polymyxin B-immobilized fiber 388 improves hyperdynamic state in MRSA septic patients. Intensive Care Med. 1997;23: 389

390

130-131.




Figure 1




Figure 2